It is the first-in-class siRNA to lower cholesterol and keep it low with two doses a year (Novartis)
Diabetes News Service
It is the first-in-class siRNA to lower cholesterol and keep it low with two doses a year (Novartis)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com